Bms Medical company information, Employees & Contact Information

BMS Joins the In Vivo Cell Therapy Chase With $1.5B Orbital Therapeutics Acquisition MedCity News

Irish Horizons: Sitting Down With BMS’ Karen Costello The Medicine Maker

Immunology Drug Sotyktu Will Kick Off Bristol Myers Squibb’s New Direct-to-Patient Platform MedCity News

BMS at Yard 56 Johns Hopkins Medicine

(apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu Business Wire

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Bristol Myers Squibb

Taben Hale, PhD The University of Arizona College of Medicine – Phoenix

Innovating for the future of medicine WashU

Bristol Myers Squibb Moves Into In Vivo CAR T with $1.5 Billion Orbital Buy Inside Precision Medicine

Prime Medicine Inks Up-to-$3.5B Collaboration with BMS, Narrows Pipeline Genetic Engineering and Biotechnology News

Pfizer adds J&J, BMS vet James List to its executive roster as new chief internal medicine officer Fierce Biotech

Prime Medicine shrinks CRISPR ambitions and gets cash infusion from Bristol Myers Squibb statnews.com

Bristol Myers Squibb Foundation, Texas Children's Global HOPE, & Baylor College of Medicine Global Health Launch Program to Combat Sickle Cell Disease in Sub-Saharan Africa PR Newswire

BMS Immunotherapy Combo Gets Two FDA Nods for GI Cancers in Span of a Week MedCity News

Yard 56 Gynecology/Obstetrics and Children's Medical Practice Clinics Johns Hopkins Medicine

Harnessing Translational Medicine to Guide Drug Discovery and Development Bristol Myers Squibb

Global Heart Failure Consortium led by Perelman School of Medicine Bristol Myers Squibb

Cytokinetics Heart Drug’s Trial Data Look Competitive With BMS Med Camzyos MedCity News

Exploring new aspects of tumor biology & possible composite biomarker approach to precision medicine Bristol Myers Squibb

Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb MedCity News

Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics MedCity News

Bristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio in $286M Deal MedCity News

Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline BioSpace

Bristol Myers Squibb's next-gen autoimmune med starts high-stakes FDA review amid classwide JAK scrutiny Fierce Pharma

BMS pays $110M to form T-cell therapy pact, helping Prime buy time to advance prioritized pipeline Fierce Biotech

Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy Fierce Pharma

BMS shows what’s NEX-T for CAR T, plus its strategy for next-gen cancer cell therapy MedCity News

Bristol Myers Squibb Is Paying $350M to Expand Its Reach in Radiopharmaceuticals to Prostate Cancer MedCity News

BMS-Ambrx collab runs out of steam after FA relaxin med canned Fierce Biotech

2seventy suffers sales slump on high production charges for BMS-partnered CAR-T med Abecma Fierce Pharma

FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in Decades MedCity News

ESC 2022: BMS, J&J's secondary stroke med falls short in phase 2, but companies see enough potential to push forward Fierce Biotech

BMS Strengthens Schizophrenia, AD Portfolio with $14B Acquisition of Karuna Therapeutics Inside Precision Medicine

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies GlobeNewswire

Bristol Myers Squibb’s Sotyktu Meets Goals in Two Pivotal Psoriatic Arthritis Studies MedCity News

BMS Inserts Cash Into Prime Medicine’s Gene-Editing Ambitions Citeline News & Insights

AHA: Bristol Myers, Janssen look to phase 3 as anticoagulant med aces proof-of-concept study Fierce Biotech

FDA rejects Xspray's would-be rival to Bristol Myers' Sprycel on dosing, manufacturing concerns Fierce Pharma

BMS Pays $100M Upfront for Antibody Degrader Conjugate from Orum Inside Precision Medicine

BMS Acquires KRAS Targeter Mirati in $4.8B Deal Inside Precision Medicine

BMS Buys Into BioNTech Bispecific Antibody, Putting Up $1.5B to Collaborate in Multiple Cancers MedCity News

BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate ACS Publications

Bristol Myers Squibb Cancer Immunotherapy Flunks a Key Test in Melanoma MedCity News

AI Proteins Inks Potential $400M Deal with BMS for AI Drug Discovery Inside Precision Medicine

Eisai and BMS End ADC Deal, But Eisai Will Continue Development Inside Precision Medicine

Roche, BMS to Leverage Digital Pathology to Validate Clinical Trial Assays Inside Precision Medicine

Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481 ACS Publications

Bristol Myers' subsidiary behind cancer blockbuster Abraxane slapped with FDA warning letter Fierce Pharma

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165 ACS Publications

Prime Medicine Secures $55 Million Deal with Bristol Myers Squibb to Develop Next-Gen T-Cell Therapies SynBioBeta

Digital pathology startup PathAI closes $75M Series B round with investments from BMS, Merck MedCity News

Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity ACS Publications

Biohaven to take a chance on Bristol Myers' once-failed DMD med Fierce Biotech

Celgene, say goodbye to Otezla: BMS agrees to sell psoriasis drug to clear $74B merger Fierce Pharma

Incyte's claims that Bristol Myers-Squibb IDO medication was stolen by ex-staffer set for trial hearing Fierce Biotech

Pfizer, BMS' Eliquis takes J&J's next-gen anticoagulant market-share crown Fierce Pharma

BMS to Use Natera’s Signatera ctDNA Assay in Adjuvant Opdivo NSCLC Trial Inside Precision Medicine

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer The New England Journal of Medicine

Reem Hospital and Bridgeway Medical Systems unveil medical equipment store Gulf News

The top 15 best-selling cancer drugs in 2022 Fierce Pharma